DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i
OrderPoint was designed as an advanced DTR solution from its first release in 2016.
Genentech will be granted an exclusive license to develop and commercialize the degrader worldwide, and will be fully responsible for the development and commercialization costs.
The study concluded that elevated levels of two proteins help predict how a person will recover from a traumatic brain injury (TBI), providing important information to determine appropriate care
Collaboration supports multiple discovery efforts, including vaccines
The card-to-cloud device was launched into the U.S. and many other markets and is designed to work without an embedded communications module.
WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".
The approved product has an estimated market size of around US$ 606 million for the twelve months ending June 2022, according to IQVIA.
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
Subscribe To Our Newsletter & Stay Updated
